A top biotech fund just made a bold move while Celcuity trades near record highs—here’s what they might see coming next.

The biotechnology industry is still a growth industry. Investing in an ETF gives me exposure to an industry I don't fully understand. The two major ETFs in the industry have different portfolio ...

In the world of biotechnology investing, companies often struggle to bring new drugs to market. Developing treatments for rare diseases can be incredibly expensive, and because these conditions affect ...

The biotech sector, tracked by iShares Biotechnology ETF, rallied 40% in six months on rising M&A activity, still below four-year levels. Read why IBB ETF is a hold.

After being mostly down over the past three years, the biotech sector rallied hard to end 2023. The SPDR S&P Biotech ETF (NYSEARCA:XBI) is up 31% in the last three months. From 2010 through 2019, ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for ...

Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, EBITDA Accretion and Cashflow Generation ...